| Autor: |
Fecikova S; National Institute of Lung Disaeses, Thorax Surgery and Tuberculosis, Vysoke Tatry, Slovakia., Csaderova L; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Centre for Advanced Materials Application, Slovak Academy of Sciences, Bratislava, Slovakia., Belvoncikova P; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Mabpro, a.s., Bratislava, Slovakia., Puzderova B; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Mabpro, a.s., Bratislava, Slovakia., Bernatova K; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Talac T; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia., Pastorek J; Mabpro, a.s., Bratislava, Slovakia., Barathova M; Institute of Virology, Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia.; Mabpro, a.s., Bratislava, Slovakia. |
| Abstrakt: |
Lung cancer represents the leading cause of cancer-related deaths. Non-small cell lung cancer (NSCLC), the most common form of lung cancer, is a molecularly heterogeneous disease with intratumoral heterogeneity and a significant mutational burden associated with clinical outcome. Tumor microenvironment (TME) plays a fundamental role in the initiation and progression of primary de novo lung cancer and significantly influences the response of tumor cells to therapy. Hypoxia, an integral part of the tumor microenvironment and a serious clinical phenomenon, is associated with increased genetic instability and a more aggressive phenotype of NSCLC, which correlates with the risk of metastasis. Low oxygen concentration influences all components of TME including the immune microenvironment. Hypoxia-inducible pathway activated in response to low oxygen supply mediates the expression of genes important for the adaptation of tumor cells to microenvironmental changes. A highly active transmembrane hypoxia-induced metalloenzyme - carbonic anhydrase IX (CAIX), as a part of transport metabolon, contributes to the maintenance of intracellular pH within physiological values and to the acidification of the extracellular space. CAIX supports cell migration and invasion and plays an important role in NSCLC tumor tissue and pleural effusion. Due to its high expression, it also represents a potential diagnostic differential biomarker and therapeutic target in NSCLC. To test new potential targeted therapeutic compounds, suitable models are required that more faithfully simulate tumor tissue, TME components, and spatial architecture. |
